Within Europe , the use of AOD-9604 at a 5-milligram dosage is increasingly subject to limited availability and extensive investigation. Although preliminary studies suggests potential benefits for specific conditions, regulatory agencies are upholding a strict approach due to insufficient long-term safety information. Consequently , user access is